PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"27012973","Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options","Afrin LB, Butterfield JH, Raithel M, Molderings GJ.","Ann Med. 2016;48(3):190-201. doi: 10.3109/07853890.2016.1161231. Epub 2016 Mar 25.","Afrin LB","Ann Med","2016","2016/03/26","","","10.3109/07853890.2016.1161231"
"37243761","A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms","Molderings GJ, Afrin LB.","Naunyn Schmiedebergs Arch Pharmacol. 2023 May 27. doi: 10.1007/s00210-023-02545-y. Online ahead of print.","Molderings GJ","Naunyn Schmiedebergs Arch Pharmacol","2023","2023/05/27","","","10.1007/s00210-023-02545-y"
"36043493","The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications","Kell DB, Pretorius E.","Biochem J. 2022 Aug 31;479(16):1653-1708. doi: 10.1042/BCJ20220154.","Kell DB","Biochem J","2022","2022/08/31","PMC9484810","","10.1042/BCJ20220154"
"35982335","Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series","Weinstock LB, Brook JB, Molderings GJ.","Naunyn Schmiedebergs Arch Pharmacol. 2022 Nov;395(11):1441-1447. doi: 10.1007/s00210-022-02282-8. Epub 2022 Aug 19.","Weinstock LB","Naunyn Schmiedebergs Arch Pharmacol","2022","2022/08/18","PMC9388361","","10.1007/s00210-022-02282-8"
"35736349","Connecting the Dots in Emerging Mast Cell Research: Do Factors Affecting Mast Cell Activation Provide a Missing Link between Adverse COVID-19 Outcomes and the Social Determinants of Health?","da Silveira Gorman R, Syed IU.","Med Sci (Basel). 2022 May 28;10(2):29. doi: 10.3390/medsci10020029.","da Silveira Gorman R","Med Sci (Basel)","2022","2022/06/23","PMC9228930","","10.3390/medsci10020029"
"35174041","Evaluation and Classification of Mast Cell Disorders: A Difficult to Manage Pathology in Clinical Practice","Leru PM.","Cureus. 2022 Feb 13;14(2):e22177. doi: 10.7759/cureus.22177. eCollection 2022 Feb.","Leru PM","Cureus","2022","2022/02/17","PMC8841127","","10.7759/cureus.22177"
"35062788","Post-HPV-Vaccination Mast Cell Activation Syndrome: Possible Vaccine-Triggered Escalation of Undiagnosed Pre-Existing Mast Cell Disease?","Afrin LB, Dempsey TT, Weinstock LB.","Vaccines (Basel). 2022 Jan 16;10(1):127. doi: 10.3390/vaccines10010127.","Afrin LB","Vaccines (Basel)","2022","2022/01/22","PMC8779641","","10.3390/vaccines10010127"
"34445665","Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis","Seidel H, Hertfelder HJ, Oldenburg J, Kruppenbacher JP, Afrin LB, Molderings GJ.","Int J Mol Sci. 2021 Aug 20;22(16):8960. doi: 10.3390/ijms22168960.","Seidel H","Int J Mol Sci","2021","2021/08/27","PMC8396658","","10.3390/ijms22168960"
"32920235","Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome","Afrin LB, Weinstock LB, Molderings GJ.","Int J Infect Dis. 2020 Nov;100:327-332. doi: 10.1016/j.ijid.2020.09.016. Epub 2020 Sep 10.","Afrin LB","Int J Infect Dis","2020","2020/09/13","PMC7529115","","10.1016/j.ijid.2020.09.016"
"32377770","Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness","Molderings GJ, Dumoulin FL, Homann J, Sido B, Textor J, Mücke M, Qagish GJ, Barion R, Raithel M, Klingmüller D, Schäfer VS, Hertfelder HJ, Berdel D, Tridente G, Weinstock LB, Afrin LB.","Naunyn Schmiedebergs Arch Pharmacol. 2020 Sep;393(9):1573-1580. doi: 10.1007/s00210-020-01886-2. Epub 2020 May 6.","Molderings GJ","Naunyn Schmiedebergs Arch Pharmacol","2020","2020/05/08","PMC7419348","","10.1007/s00210-020-01886-2"
"32328892","Mast Cell Activation Syndrome: A Primer for the Gastroenterologist","Weinstock LB, Pace LA, Rezaie A, Afrin LB, Molderings GJ.","Dig Dis Sci. 2021 Apr;66(4):965-982. doi: 10.1007/s10620-020-06264-9. Epub 2020 Apr 23.","Weinstock LB","Dig Dis Sci","2021","2020/04/25","","","10.1007/s10620-020-06264-9"
"31994488","Restless legs syndrome is associated with mast cell activation syndrome","Weinstock LB, Walters AS, Brook JB, Kaleem Z, Afrin LB, Molderings GJ.","J Clin Sleep Med. 2020 Mar 15;16(3):401-408. doi: 10.5664/jcsm.8216. Epub 2020 Jan 14.","Weinstock LB","J Clin Sleep Med","2020","2020/01/30","PMC7075100","","10.5664/jcsm.8216"
"30874862","[Surgical interventions in patients with systemic mast cell activation disease : Recommendations for perioperative management]","Sido B, Homann J, Hertfelder HJ, Zienkiewicz T, Christians KP, Schablin P, Mücke M, Molderings GJ.","Chirurg. 2019 Jul;90(7):548-556. doi: 10.1007/s00104-019-0935-z.","Sido B","Chirurg","2019","2019/03/16","","","10.1007/s00104-019-0935-z"
"30249726","Mast cell deposition and activation may be a new explanation for epiploic appendagitis","Weinstock LB, Kaleem Z, Selby D, Afrin LB.","BMJ Case Rep. 2018 Sep 23;2018:bcr2018224689. doi: 10.1136/bcr-2018-224689.","Weinstock LB","BMJ Case Rep","2018","2018/09/26","PMC6157556","","10.1136/bcr-2018-224689"
"29951321","Management of a Parturient with Mast Cell Activation Syndrome: An Anesthesiologist's Experience","Kumaraswami S, Farkas G.","Case Rep Anesthesiol. 2018 May 22;2018:8920921. doi: 10.1155/2018/8920921. eCollection 2018.","Kumaraswami S","Case Rep Anesthesiol","2018","2018/06/29","PMC5987329","","10.1155/2018/8920921"
"29864098","Activity and Exercise Intolerance After Concussion: Identification and Management of Postural Orthostatic Tachycardia Syndrome","Miranda NA, Boris JR, Kouvel KM, Stiles L.","J Neurol Phys Ther. 2018 Jul;42(3):163-171. doi: 10.1097/NPT.0000000000000231.","Miranda NA","J Neurol Phys Ther","2018","2018/06/05","PMC6023605","","10.1097/NPT.0000000000000231"
"29770197","Case Report: Treatment of systemic mastocytosis with sunitinib","Molderings GJ, Afrin LB, Hertfelder HJ, Brettner S.","F1000Res. 2017 Dec 28;6:2182. doi: 10.12688/f1000research.13343.1. eCollection 2017.","Molderings GJ","F1000Res","2017","2018/05/18","PMC5946163","","10.12688/f1000research.13343.1"
"29743606","White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome","Haenisch B, Molderings GJ.","Transl Psychiatry. 2018 May 10;8(1):95. doi: 10.1038/s41398-018-0143-5.","Haenisch B","Transl Psychiatry","2018","2018/05/11","PMC5943358","","10.1038/s41398-018-0143-5"
"29667234","Can H(2) -receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? A case report","Allen SJ, Chazot PL, Dixon CJ.","Br J Clin Pharmacol. 2018 Jul;84(7):1611-1616. doi: 10.1111/bcp.13578. Epub 2018 Apr 18.","Allen SJ","Br J Clin Pharmacol","2018","2018/04/19","PMC6005605","","10.1111/bcp.13578"
"29225779","Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA","Molderings GJ, Zienkiewicz T, Homann J, Menzen M, Afrin LB.","F1000Res. 2017 Oct 26;6:1889. doi: 10.12688/f1000research.12730.1. eCollection 2017.","Molderings GJ","F1000Res","2017","2017/12/12","PMC5710302","","10.12688/f1000research.12730.1"
"29222399","Pediatric Disorders of Orthostatic Intolerance","Stewart JM, Boris JR, Chelimsky G, Fischer PR, Fortunato JE, Grubb BP, Heyer GL, Jarjour IT, Medow MS, Numan MT, Pianosi PT, Singer W, Tarbell S, Chelimsky TC; Pediatric Writing Group of the American Autonomic Society.","Pediatrics. 2018 Jan;141(1):e20171673. doi: 10.1542/peds.2017-1673. Epub 2017 Dec 8.","Stewart JM","Pediatrics","2018","2017/12/10","PMC5744271","","10.1542/peds.2017-1673"
"28905193","Siglec-8 as mast cell selective target: developing paradigms amidst inconvenient truths","Molderings GJ.","Naunyn Schmiedebergs Arch Pharmacol. 2017 Nov;390(11):1173-1175. doi: 10.1007/s00210-017-1425-9. Epub 2017 Sep 14.","Molderings GJ","Naunyn Schmiedebergs Arch Pharmacol","2017","2017/09/15","","","10.1007/s00210-017-1425-9"
"28386644","Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing","Altmüller J, Haenisch B, Kawalia A, Menzen M, Nöthen MM, Fier H, Molderings GJ.","Immunogenetics. 2017 Jun;69(6):359-369. doi: 10.1007/s00251-017-0981-y. Epub 2017 Apr 6.","Altmüller J","Immunogenetics","2017","2017/04/08","","","10.1007/s00251-017-0981-y"
